"Think of me as your personal diabetes assistant. In this app, you and I are partners, so let's get started." Those words are part of a greeting from the Sugar.IQ personal diabetes assistant, an app powered by IBM Watson's cognitive computing technology that is available to users of Medtronic's Guardian Connect mobile continuous glucose monitoring system. Indeed, we are in the midst of an era in which an increasing number of wearable continuous glucose monitors (CGMs) are receiving Food and Drug Administration (FDA) approval, and many of these systems come with app-based readers to enhance their convenience and facilitate the coordination of care for people with type 1 diabetes with their healthcare providers. A recent publication in Nature Biotechnology provides a comprehensive overview of the state of CGMs and the global research efforts toward the development of the holy grail of consumer-friendly glucose sensors for people with type 1 diabetes: devices that are pain free, noninvasive, continuous, and wearable (1 ).
The components of most CGMs include a sensor, a transmitter, and a receiver/display device (compatible smart device/phone with a device-specific mobile app/ receiver). The sensor conducts a glucose oxidase-based electrochemical analysis of the surrounding interstitial fluid, and the resulting current is sent through a wire to an adhesive patch (typically worn on the abdomen or arm), which wirelessly transmits the reading to an app/ mobile device.
The primary benefit of CGMs compared to selfmonitoring blood glucose devices is the ability to acquire data in a manner that enables diabetic patients and their healthcare providers to dynamically assess glucose concentrations and trends. Data from clinical trials have demonstrated improved patient outcomes for CGM us-ers as a result of the increased awareness of their glucose concentrations. Accordingly, the use of CGMs is recommended by national and international medical organizations and expert clinician panels. An overview of a subset of CGMs that have received FDA approval in the past 5 years is provided in Table 1 . Among the differentiating features of these devices is the age of the patients for each device's intended use. The recent improvement in the accuracy of CGMs prompted the FDA to label some devices as safe for the nonadjunctive dosing of insulin; however, this action has been met with considerable reticence regarding evidence that CGMs are subject to sporadic, unpredictable, and large errors.
Despite being touted for their convenience, CGMs are not without considerable safety risks that are mostly related to the insertion of the CGM sensor into a user's skin, as reported in the FDA Safety and Effectiveness Data reports for most CGM systems. Additional risks are related to an inaccurate sensor value outside of the patient's target range, missed alerts, false alerts, falsenegative hypoglycemia vs hyperglycemic readings, and false-positive hypoglycemia vs hyperglycemia.
Despite these challenges, next-generation CGMs provide unprecedented convenience for patients. Given the rapid increase in the insulin-dosing dependent diabetes population worldwide, there is a growing need for the continued development of CGMs that are even smaller, more convenient, more accurate, and as minimally invasive as possible. 
